

Sierra Leone

Support for Vaccine: Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme

1. **Country:** Sierra Leone

2. **Vaccine grant number:** SLE-HPV-R

3. **Date of Decision Letter:** 29 September 2020

4. **Date of the Partnership Framework Agreement:** 10 March 2013

5. **Programme title:** New Vaccine Support (NVS), Human Papillomavirus Vaccine (HPV), Routine

6. **Vaccine type:** Human Papillomavirus Vaccine (HPV)

7. **Requested product presentation and formulation of vaccine:**

HPV4, 1 dose/vial, liquid

8. **Programme duration:**¹ 2019-2021

9. **Programme Budget (indicative):**²³ (subject to the terms of the Partnership Framework Agreement, if applicable)

	2019-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget(US\$)	17,738	892,659	-	-	-	-	910,397

10. **Vaccine introduction grant:**

Approval		
Year	Grant number	Amount (US\$)
2019	SLE-HPV-R-VIG	255,322

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³ This is the amount that Gavi has approved.

12. Indicative annual amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)

11. Product switch grant:

Not applicable

Type of supplies to be purchased with Gavi funds	2019-2020	2021	2022
Number of vaccine doses	-	193,900	-
Number of AD syringes ⁴	-	227,100	-
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	2,500	-
Annual Amounts (US\$)	17,738	892,659	-

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:	Initial self-financing				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2021	2022	2023	2024	2025
Number of vaccine doses	23,500	-	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-

⁴ The Injection Safety Devices for HPV were already paid for under the 2020 program year although the vaccines were not shipped at that time due to the delay in the start of HPV introduction. This wasn't taken into account during review/approval processes, therefore the HPV Decision Letter for 2021 also includes devices. Please note that an adjustment will be made in future to balance the devices.

Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	105,750	-	-	-	-
Total co-financing payments (US\$) (including freight)	106,938	-	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>


18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable

Signed by,
On behalf of Gavi,



Pascal Bijleveld,
Director Country Support
30 September 2020